daiichi sankyo company limited japanese 第一三共株式会社 hepburn daiichi sankyō kabushikigaisha global pharmaceutical company secondlargest pharmaceutical company japan achieved jpy billion revenue company owns american biotechnology company plexxikon american pharmaceutical company american regent german biotechnology company pharma recently sold ranbaxy laboratories india daiichi sankyo co ltd producer benicar olmesartan angiotensin ii receptor antagonist top selling drug us global sales olmesartan billion yen daiichi sankyo inc dsi began operating us us subsidiary daiichi sankyo company limited member daiichi sankyo group organization includes us commercial operations global clinical development daiichi sankyo pharma development headquartered basking ridge new jersey daiichi sankyo europe gmbh dse european subsidiary headquartered munich germany organization responsible development manufacturing european countries daiichi sankyo company limited full member european federation pharmaceutical industries associations efpia international federation pharmaceutical manufacturers associations ifpma daiichi sankyo established merger sankyo company limited 三共株式会社 sankyō kabushiki kaisha daiichi pharmaceutical company limited 第一製薬株式会社 daiichi seiyaku kabushiki kaisha centuryold pharmaceutical companies based japan sankyo co ltd founded jokichi takamine patented isolation takamine president sankyo co ltd march july sankyo acquired german luitpoldwerk group pharmaceutical company based luitpold renamed american regent american regent based united states subsidiary daiichi daiichi sankyo acquired zepharma otc drugs unit astellas pharma june company agreed take majority stake indian generic drug maker ranbaxy deal valued acquired pharma june contributing therapeutic antibody companys anticancer company closed pharma acquisition plexxikon berkeley californiabased pharmaceutical startup company completed april million additional million milestone payments pending success vemurafenib plexxikons lead program oral novel drug targets oncogenic braf mutation present half melanoma cancers eight percent solid tumors daiichi sankyo retaining us copromotion right roche licensed april daiichi sankyo announced agreed vote shares ranbaxy favor sun pharmas acquisition ranbaxy merger process entailed share swap transaction set close december pending shareholder court regulatory approvals customary conditions september daiichi sankyo agreed acquire ambit biosciences approximately million deal enabled daiichi gain phase iii cancer compound april company announced sold stake sun pharmaceutical industries acquired acquiring ranbaxy raising transferred products japan alfresa holdings corporation jpy billion order focus company acquired ramosetron nicardipine barnidipine astellas pharma october january companys market value rose jpy trillion us food drug administration approval release antibodydrug conjugate cancer daiichi sankyo developed enhertu cooperation agreed march pay billion daiichi sankyo exchange share enhertus shutdown plexxikon announced daiichi sankyo pivots focus antibodydrug conjugate following illustration companys major mergers acquisitions historical predecessors comprehensive list sankyo company limited daiichi pharmaceutical company limited zepharmaacq ranbaxy laboratoriesacq pharmaacq plexxikonacq ambit biosciencesacq daiichi sankyo closely monitored settling charges concerning payment remuneration physicians form speaker fees part companys physician organization discussion program violation false claims act antikickback daiichi sankyo agreed pay united states state medicaid programs million settle allegations united states department justice kickbacks part companys physician organization discussion program ran daiichi sankyo paid physicians improper kickbacks form speaker fees induce physicians prescribe daiichi sankyos drugs including azor benicar tribenzor allegedly payments made physicians even physician participants pods took turns speaking duplicative topics daiichipaid dinners recipient spoke members staff office associated dinner lavish cost exceeded daiichi sankyos internal cost limitation per schemes particularly abhorrent said inspector general daniel r levinson us department health human manufacturers physicians engage cheating medicare medicaid millions dollars threatening programs upon many elderly disabled americans rely office take whatever steps necessary guard improper alliances manufacturers drugs prescribe corporate integrity agreement closely monitoring daiichi sankyo list select midstage latestage investigational candidates daiichisankyos pipeline include httpsenwikipediaorgwikidaiichisankyo